From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history

AXA1125 or LIVRQNac is a new drug developed by Axcella Therapeutics which is currently in clinical trials for post-exertional fatigue caused by Long COVID.[1][2] AXA1125 has been described as a "novel composition of amino acids" and a "metabolic modulator" and consists of five amino acids (arginine, glutamine, isoleucine, leucine, and valine) and N-acetylcysteine (NAC).[3]

Theory[edit | edit source]

AXA1125 is a endogenous metabolic modulator, which means it consists of naturally occurring substances that act in a way that modulates energy metabolism.[3] AXA1125 was designed to treat non-alcoholic liver conditions.[3]

Amino acids and precusors[edit | edit source]

AXA1125 consists of a combination of:

Evidence[edit | edit source]

Clinicians[edit | edit source]

Risks and safety[edit | edit source]

Costs and availability[edit | edit source]

Axcella Therapeutics, the company producing and studying the drug, has closed. [4]

See also[edit | edit source]

Learn more[edit | edit source]

References[edit | edit source]

  1. "Oxford to test potential treatment for fatigue in long COVID patients". University of Oxford. Retrieved October 31, 2021.
  2. "Axcella commences trial of AXA1125 for Long COVID treatment". Retrieved October 31, 2021.
  3. 3.0 3.1 3.2 3.3 Hamill, Michael J.; Nadine Daou; Arianna Nitzel; Lorena Pantano; Margaret Koziel; Manu V. Chakravarthy (March 2021). "Mechanistic Insights Into AXA1125, a Novel Endogenous Metabolic Modulator Composition, Targeting Multiple NASH Drivers" (PDF). Axcella Health Inc.
  4. "Axcella Health Becomes the Latest Flagship Company to Close its Doors". BioSpace. Retrieved May 8, 2024.